Author of

• 11946

  +

  P2.24 - Poster Session 2 - Supportive Care (ID 157)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11957

    +

    P2.24-011 - Left Ventricular Thormbosis due to Chemotherapy using Bevacizumab for Lung Cancer. (ID 887)

    09:30 - 09:30  |  Author(s): H. Tachi
    • Abstract

    Background
    Thoromboembolism has been reported as one of side effects of bevacizumab (BEV). An occurrence frequency of venous thoromboembolism caused by BEV is 0.2%. Specifically, it increases to approximately 4% within 1 to 3 months soon after chemotherapy. However, a ventricular thormbosis caused by BEV has almost never reported as far. We report a case of a ventricular thormbosis that occurred during chemotherapy using BEV for the lung cancer.

    Methods
    (case) 55 year-old, Japanese woman, who suffered myocardial infarction at 27 year-old and had a history of smoking (B.I.:350), complained of left.hemiplegia for brain tumor at first. After surgical treatment for brain tumor, she was diagnosed as lung adenocarcinaoma, cT1aN3M1b stage IV and was referred to our hospital. The first line pemetrexed(500 mg/m2) / carboplatin (AUC 6) /BEV (15 mg/kg) chemotherapy for two cycles every 3 weeks was performed. A partial response was found in the initial computed tomography (CT) evaluation, whereas the examination showed a thrombus of 26 × 25 mm in diameter in the left ventricle. D-dimer is 2.0 μg / mL at this point (D-dimer before treatment is 1.5 μg / mL). The anticoagulation therapy by using heparin continuous infusion and sequential oral agent therapy of warfarin and aspirin reduced the thrombus to 11 × 22 mm in diameter.

    Results
    (Discussion) Thromboembolism is clinically diagnosed by clinical findings, ultrasonography, contrast CT, and D-dimer. D-dimer is a simple indicator even for asymptomatic thrombus formation and has been reported to be valid for the evaluation of thrombus formation. In this case, D-dimer value was almost conserved through this event. We cannot be undeniable the relation the chemotherapy including BEV and left ventricular thrombosis. Also, since there is no evaluation of left ventricular function before chemotherapy treatment, it can not be denied the possibility of thrombus formation by reduced left ventricular function.

    Conclusion
    (conclusion) We have experienced a case that developed ventricular thrombosis during chemotherapy for lung cancer. It is believed to be evaluated, such as ultrasonography before using BEV in the case passing a long period of time after myocardial infarction.